Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212583 · ClinicalTrials.gov registry record · Phase 2
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
A Phase 2 study of Prostate Cancer and Oligometastatic Disease, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT06212583 is a Phase 2 study of Prostate Cancer and Oligometastatic Disease that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 88 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06212583, a Phase 2 study of Prostate Cancer and Oligometastatic Disease, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of care and addition of 6-months of niraparib/abiraterone acetate combination pills and prednisone for participants with recurrent metastatic prostate cancer.
Conditions Studied
Interventions
- RADIATION Stereotactic ablative radiation therapy (SABR)
- DRUG Androgen deprivation therapy (ADT)
- DRUG niraparib/abiraterone acetate
Study Locations (1)
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06212583
The ClinicalTrials.gov registry entry for NCT06212583 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic ablative radiation therapy (SABR) is the first listed.
NCT06212583 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06212583 about?
NCT06212583 is a clinical study titled "High-Risk Metachronous Oligometastatic Prostate Cancer Trial". The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of care and addition of 6-months of niraparib/abiraterone acetate combinat...
What is the current status of trial NCT06212583?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2024-04-17. Estimated completion is 2029-12-31.
What conditions does trial NCT06212583 study?
This clinical trial studies the following conditions: Prostate Cancer, Oligometastatic Disease.
What interventions are being tested in trial NCT06212583?
The interventions under investigation include: Stereotactic ablative radiation therapy (SABR) (RADIATION), Androgen deprivation therapy (ADT) (DRUG), niraparib/abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT06212583?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06212583 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.